Related Experiment Video
Updated: Aug 24, 2026
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Real-time quantification of TEL-AML1 fusion transcripts for MRD detection in relapsed childhood acute lymphoblastic
Tillmann Taube1, Cornelia Eckert, Gabriele Körner
1Klinik für Pädiatrie mit Schwerpunkt Onkologie/Hämatologie, Otto-Heubner Centrum für Kinder- und Jugendmedizin, Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin, Forschungshaus 37, 3353 Berlin, Germany. tillmann.taube@charite.de
Abstract:
Response to therapy of ALL assessed by molecular methods has been proved to be a predictor of outcome. Alternatively to established but very labour-intensive DNA-based PCR-techniques the TEL-AML1 fusion transcript can serve as a marker for MRD monitoring. MRD quantification using TEL-AML1 is of particular interest if the results are directly comparable to data obtained by established DNA-based assays. Investigation of the potential of MRD monitoring using LightCycler technology for TEL-AML1 real-time quantification and comparison to results from established DNA-based MRD assays revealed corresponding results. Accordingly, TEL-AML1 MRD quantification is a sensitive, specific and rapid method that can supplement clone-specific MRD detection.